Feb 22 2022

Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually

By |2022-02-21T18:59:51-05:00February 22nd, 2022|Featured, Investor News, Medical, News, Press Releases|1 Comment

Jackson Center, PA, February 22, 2022 – Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases.  With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens.  See Table Below.  This could lead to ...

Read More
Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By |2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Read More
INVESTOR/MEDIA INQUIRIES

MEDICAL METAVERSE

As part of our efforts to remain at the forefront of breakthrough technologies in the medical and scientific fields, Halberd Corporation is engaged in scientific study and research in the fields of medicine, the prevention, treatment and management of illness and infections and rapid tests to identify infection, and other medical maladies.

To learn more about how we can further your efforts, or to partner with Halberd on specific healthcare solutions, please email: info@halberdcorporation.com

© Copyright 2019 - | Halberd Corporation | All Rights Reserved
TwitterEmail
Go to Top